Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future
PR96312
NANJING, China, June 2, 2022 /PRNewswire=KYODO JBN/--
Vazyme, China's leading biotechnology company, has recently released its 2021
annual report, revealing that the company has maintained a steady and solid
growth throughout the past year. The report shows that it has achieved $289
million in operating income with an increase of 19.44% year-on-year. The
company's R&D investment reached $36 million, up 83.47%, representing 12.33% of
its total operating income.
"The year 2022 is still full of opportunities and challenges. We will continue
to strengthen care technology based on the protein technology platform. Vazyme
has been dedicated to our mission 'Science and Technology Make a Healthier
Life' to focus on technology innovation and continuously expand the application
fields of care technologies in life science, biomedicine, in vitro diagnostics,
animal health and synthetic biology in human health. We have been holding
ourselves to pursue the highest standards in quality of products and services
for our customers and partners. Our global business network and operations make
sure we could be close to the local markets, and more importantly, to do as
much it can to meet the unmet customers' needs", said Cao Lin, chairman and
founder of Vazyme.
This year also marks the Vazyme's 10th anniversary. Moving forward, the company
plans to ramp up efforts in R&D and innovation, continuously upgrade and
transform its core technologies, and expand business in new sectors. As one of
the few R&D-focused biotech company in China, Vazyme holds a longstanding
commitment in technology innovation. Over 2000 papers have been published by
Vazyme in top academic journals worldwide, including more than 260 in
CNS(stands for Cell, Nature, Science). By 2022, it has some 3000 employees and
27% of that are in the R&D team.
"Looking ahead, we will make further inroads in our key businesses and expand
into new domains. I believe the market demand for COVID-19 and other related
detection materials and products will continue to be strong. During the
pandemic, China has remained one of the largest supplier for COVID-19 detection
products." said Cao. In addition to pandemic-induced detection businesses,
other regular detection products will be further developed, according to Cao.
"When the prevention and control of the pandemic become regular, there will be
new demands for detection products. In the future we will focus on the
development of that," added Cao.
Vazyme can not only provide COVID-19 and other related detection materials and
products, but only offer various products and solutions in life-science
industry for universities, laboratories, and related R&D centers, such as
scientific research reagents, NGS Library Prep Kits and molecular diagnostics
solutions. Currently, Vazyme has over 200 kinds of genetic engineering
recombinases, more than 1,000 kinds of high-performance antigens, monoclonal
antibodies, and other key raw materials, in addition to over 600 finished
products.
As Vazyme's 10th anniversary slogan "Together for a Better Future", Vazyme aims
to get close to its partners for a better future. In the future, Vazyme will
provide better products and solutions, contribute to improve R&D efficiency for
its partners, realize more scientific breakthroughs and dedicating to the
mission "Science and Technology Make a Healthier Life".
SOURCE: Vazyme
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=422623
Caption: Vazyme
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。